Mannkind: Overlooked Biotech With Excellent Prospects (Part VI)

Part VI: Conclusion – Summary, valuation, and risks

This is the final part of my six-part series on Mannkind (MNKD). Be sure to see Part 1, Part 2, Part 3, Part 4, and Part 5, if you have not done so already. I will now summarize the key points and get into valuation.

Mannkind is a development-stage biotech company, which is close to filing for FDA approval for its first product, Technosphere Insulin. (They have some other products in their pipeline, all in early stages, but they’re not so important. See Part 5 for more discussion about them.) Technosphere Insulin is an inhaled form of meal-time insulin with 4 key advantages. (See Part 1 and Part 3 for more details).